EU Clinical Trials & Advanced Therapies Regulations, CTR 536/2014 & ATMP Standards
Track Clinical Trials Regulation (EU) No 536/2014 execution, CTIS single-portal authorizations, Advanced Therapy Medicinal Product (ATMP) approvals, and GMO clinical trial derogations.
Clinical Trials, Biotech & ATMPs Regulatory Landscape & Compliance Overview
Official IntelligencePolicyIndex indexes real-time gazette notifications, policy orders, tariff determinations, and compliance circulars issued across the Clinical Trials, Biotech & ATMPs sector. Regulatory intelligence is aggregated across central ministries, state regulatory commissions, and statutory authorities.
Statutory Directives
Official Extraordinary Gazettes, S.O. & G.S.R. orders, and executive notifications.
Compliance Mandates
Sector-specific regulatory obligations, licensing norms, and statutory filing guidelines.
Other Verticals in Healthcare, Pharmaceuticals & Life Sciences
Looking for Weekly Policy & Regulatory Briefings?
Access curated sector roundups, executive summaries, and downloadable PDF intelligence reports.
Official Clinical Trials, Biotech & ATMPs Gazettes & Notifications
Frequently Asked Questions on Clinical Trials, Biotech & ATMPs Regulations
How does the Clinical Trials Regulation (CTR 536/2014) streamline clinical studies?
The CTR replaced national trial authorisations with a single harmonised application submitted via the Clinical Trials Information System (CTIS) portal, accompanied by a coordinated assessment across all reporting and concerned Member States.
How does the GMO Deliberate Release Directive interact with gene therapy clinical trials?
Directive 2001/18/EC requires an environmental risk assessment for any deliberate release of GMOs, including gene therapy vectors used in clinical trials. The Clinical Trials Regulation provides for simplified, coordinated GMO assessments for investigational medicinal products containing or consisting of GMOs, reducing duplication between national GMO authorities and clinical trial assessors.
What is the regulatory pathway for Advanced Therapy Medicinal Products (ATMPs) in the EU?
ATMPs (gene therapies, somatic cell therapies, tissue-engineered products, and combined ATMPs) require mandatory centralised marketing authorisation through the EMA, with scientific evaluation by the Committee for Advanced Therapies (CAT). Manufacturers must hold GMP certification, and the hospital exemption allows non-routine ATMPs to be prepared on a non-industrial basis under national rules.